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Abstract 
Background 
In 2005 there was an outbreak of XDR (extensively 
drug resistant) TB in Tugela Ferry, which is served 
by the Church of Scotland Hospital (COSH), in the 
uMzinyathi District, KwaZulu-Natal, South Africa. 
An investigation was carried out to determine if 
XDR TB was occurring elsewhere in the province, 
and to develop hypotheses for the rise in drug 
resistance with a view to developing a strategy for 
the control of MDR (multi-drug resistant) and XDR 
TB in the province and elsewhere. 
Methods 
TB incidence and treatment success rates, for each 
of the 11 districts in the province, were obtained 
from the provincial electronic TB register for the 
years 2002−2007. The results of culture and drug 
sensitivity tests for the years 2002 to 2007 in each 
of the districts were compiled and culture taking 
practices were compared to the number of MDR 
TB cases. Interviews were conducted with key 
personnel in affected sites.  
Findings 
In 2007, 2799, or 2.3% of 119,218 notified TB 
cases in the province were multi-drug resistant 
(MDR), and of these 270 (9.6%) were XDR. The 
two worst affected districts were uMzinyathi where 
226 (4.1%) of 5522 notified TB cases were MDR, 
and of these 120 (53%) were extensively drug 
resistant (XDR), and uMkhanyakude where 337 
(4.8%) of 6991 notified TB cases were MDR, but 
of these only four or (1.2%) were XDR. The worst 
affected medical centre was COSH where 164 or 
9.8% of notified TB cases were MDR and of these 
99 (60%) were XDR. 
Interpretation 
Very high rates of XDR TB in the province are 
only found in uMzinyathi district even though 
MDR TB is common in most other districts. XDR 
may arisen at COSH because of the early and 
effective integration of the TB and HIV 
programmes in overcrowded and poorly ventilated 
facilities particular to COS.H To control XDR TB 
better management of both susceptible and resistant 
forms of TB is needed including treatment 
supervision, infection control and HIV 
management. 
Introduction 
Over the last ten to twenty years resistance to TB 
drugs has increased and in some countries up to 
20% of new TB cases are infected with multi-drug 
resistant (MDR) strains of TB that are resistant to at 
least isoniazid (INH) and rifampicin (RIF).1 In 
2005 an outbreak of extensively drug resistant 
(XDR) TB was reported from Church of Scotland 
Hospital (COSH), Tugela Ferry, in the KwaZulu-
Natal Province of South Africa.2 These XDR 
patients were resistant to isoniazid and rifampicin 
but also to ethambutol (ETA), streptomycin (STP), 
aminoglycosides (kanamycin) and fluoroquinolones 
(ofloxacin). The initial investigation found that of 
475 patients with confirmed culture positive TB 
185 (39%: 35%−44%; here and elsewhere errors 
are 95% confidence limits) were MDR and that of 
these 30 (16%; 11%−22%) were XDR. Forty four 
XDR TB patients were tested for HIV and were all 
HIV-positive. Their median survival time, after 
diagnosis, was 16 days.2 The unexpected and rapid 
emergence of XDR TB, the association with HIV 
and the very high mortality was of great concern; if 
similar outbreaks were to occur more widely in the 
province, the country or the region they could lead 
to considerable mortality, jeopardize TB control 
programmes, and be very costly to contain. 
 In 2007 the KwaZulu-Natal Department of 
Health initiated an investigation of MDR and XDR 
TB in the province to establish a) the geographical 
extent of the epidemic; b) the reasons why it 
happened where and when it did; c) the nature of 
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the association with HIV; and d) ways to contain 
and control the epidemic.  
 We collected, collated and analyzed data from 
districts, hospitals and laboratories on: a) laboratory 
testing; b) culture taking practices; c) the 
prevalence of HIV; d) TB programme performance; 
and e) the management of MDR. We focussed on 
the years from which TB culture data was available, 
2001 to 2007, covering the period from four years 
before, until two years after, the start of the 
outbreak.  
Methods 
TB culture 
Between 2001 and 2007 TB cultures and drug 
sensitivity testing (DST) in KwaZulu-Natal were 
done in laboratories at the King George V (KGV) 
and Inkosi Albert Luthuli Central (IALCH) 
Hospitals. In 2006 the laboratory at KGV was 
closed and from March 2006 IALCH took 
responsibility for all cultures and DST testing in the 
province. TB culture and sensitivity data were 
available from KGV laboratory from 2001 to 2005, 
and at the IALCH laboratory from 2002 to 2007 
including: hospital number, patient name, sex, 
specimen number, type of sample (sputum, gastric 
washing and spinal fluid), referring centre, date 
received, and drug sensitivity. The hospital number, 
name, age and sex were used to clean the data and 
remove duplicates. When the same case had more 
than one culture, the result was linked to the first 
culture test and classified according to the highest 
level of drug resistance if the results differed. 
Drug resistance testing 
Prior to 2000, all samples were tested for sensitivity 
to isoniazid, rifampicin and ethambutol. If 
resistance was detected to any one drug, further 
testing was done for resistance against 
streptomycin, kanamycin and ciprofloxacin. In July 
2004, the policy at IALCH was expanded to include 
routine testing of all samples for all six of the above 
drugs since rates of resistance were increasing and 
this approach reduced the turnaround time for 
second line DST. The proportion of samples tested 
for sensitivity to all six drugs increased from 27% 
to 49%, 63% and 100% in successive years from 
2003 to 2006. Ciprofloxacin testing was replaced 
by ofloxacin in 2004 but the database at IALCH 
was not changed, and from 2004 onwards 
‘ciprofloxacin resistance’ is actually ‘ofloxacin 
resistance.’ TB cultures were prepared using the 
MGIT 960 liquid culture system followed by drug 
susceptibility testing (DST) on solid Middlebrook 
7H10 mini-plates.3,4 
 Drug resistance testing at KGV was performed 
at the referring doctor’s request. In 2004 and 2005 
KGV did not test for resistance to fluoroquinolones. 
Culture taking 
We compiled the data for liquid MGIT samples that 
were cultured in each district from 1 April 2006 to 
31 March 2007. According to the national 
guidelines, cultures should be taken at the initial 
investigation of all retreatment cases, treatment 
failures, sputum smear-negative cases with clinical 
signs of TB who do not respond to antibiotics, and 
all HIV-positive TB suspects.5 We used the 
Electronic TB Register (ETR), maintained by the 
National Department of Health, to estimate the 
number of TB cultures that should have been done 
in each district and compared this with the number 
that were done.  
HIV 
The prevalence of HIV in each district was taken 
from annual antenatal clinic sero-prevalence 
surveys, 2003 to 2006.6-9 While these data may 
tend to overestimate HIV prevalence in the general 
population, they provide a reasonable means of 
comparing the HIV burden in each district. 
TB notification data  
The number of new and retreatment TB cases 
notified each year from 2002 to 2007 and the 
treatment outcomes by district and health facility 
from 2002 to 2005 were taken from the ETR. 
Population data 
The population of each district and each hospital 
catchment area was provided by the Geographical 
Information Systems (GIS) Component of the 
Provincial Department of Health. 
MDR TB treatment 
KGV was set up as a TB hospital in the 1950s with 
over one thousand beds. With the passage of time 
and deterioration of the buildings the number of 
beds was reduced and in 2007 only 160 beds were 
available for treatment of TB patients. KGV served 
as a specialised referral hospital for MDR TB 
patients and, at the time of the study, was the only 
place in KwaZulu-Natal where MDR TB treatment 
was available. For the period 1998 to 2007 
available patient data included hospital number, 
name, age, sex, referring centre, drug sensitivity, 
date admitted and discharged, treatment outcomes, 
and HIV status. MDR outcomes were not available 
for the 2006 and 2007 cohorts, as patients had not 
completed treatment at the time of the 
investigation. We compared the number of patients 
in the province that tested positive for MDR with 
the number that were admitted to KGV between 1 
July 2006 and 30 June 2007 to assess the proportion 
of MDR patients that were admitted for treatment. 
Interviews with health service personnel 
Interviews were conducted with clinical and 
administrative hospital staff working in the 1990s 
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and 2000s at major hospitals in the two districts 
where MDR burden was the highest COSH in 
uMzinyathi, and Manguzi and Hlabisa hospitals in 
uMkhanyakude where XDR was the lowest, as well 
as a reference hospital, Edendale, in uMgungun-
dlovu district. Twelve interviews, each lasting for 
up to one hour, were carried out with the Medical 
Manger, the Chief Medical Officer, and the Chief 
Professional Nurse (TB coordinator, DOTS nurses, 
or infection control nurses).  
Provincial map 
A map of the province with the districts indicated 
for reference is given in the Appendix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The number (A) and proportion (B) of 
MDR and XDR cases in KwaZulu-Natal. Green and 
red: MDR, red MDR from COSH; blue and orange 
XDR, orange XDR from COSH. 
Results 
Time trends 
The TB notification rate in KwaZulu-Natal rose 
from about 54,000 in 2002 to over 119,000 in 2007. 
The number of MDR TB cases rose more quickly 
from 210 in 2001 to 2799 in 2007 (Figure 1A, green 
and red bars) by when 2.3% of all TB cases were 
MDR (Figure 1B, green and red bars). While some 
XDR cases were identified before 2005, the 
numbers rose very rapidly in 2005, and more 
slowly after that, with about half of all XDR cases 
being reported from COSH (Figure 1A blue and 
orange bars) in 2007. The proportion of MDR cases 
that were XDR increased from 2.1% in 2002 to 
9.6% in 2007 (Figure 1A green and red bars). 
 The substantial increase in the proportion of 
XDR cases followed the discovery of XDR TB at 
COSH in February 2005 after which case finding 
was intensified and cultures were done on all TB 
suspects at COSH. In 2006 other health facilities in 
the province began to request cultures and the 
proportion of MDR cases that were XDR, from 
outside COSH, doubled between 2005 and 2006 
(Figure 1B, blue bars). Much of the increase in the 
number of MDR and XDR cases is the result of the 
increase in the number of cultures that were done. 
In 2007, 57% more samples were cultured in the 
province compared to 2006. Unfortunately, the total 
number of samples cultured in the province was not 
available for 2005 or earlier. 
Variation among districts 
Figure 2 shows the overall TB notification rate, the 
proportion of cases that were MDR (including 
XDR) and the proportion of these that were XDR, 
averaged over the years 2006 and 2007. The 
notification rate for all forms of TB ranged from 
750 to 1400 per 100 000 population per year (blue 
bars) whereas the proportion of cases that were 
MDR ranged from 1% to 5% (red bars). However, 
46% of MDR cases were XDR in uMzinyathi, more 
than three times the proportion in uMgungundlovu, 
the next highest district, where 14% of MDR cases 
were XDR. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. TB notification rates: all forms (red), MDR as a 
proportion of all forms (blue) and XDR as proportion of 
MDR (green) for the districts in KwaZulu-Natal for 
2006-2007. 
Culture taking 
Culture taking practice varied greatly among 
districts. The cities of Durban in eThekwini and 
Pietermaritzburg in uMgungundlovu have 
specialized TB hospitals. The number of cultures 
done in these districts was 1.4 and 1.0 per TB 
patient, respectively. In the remaining districts the 
culture rate was much lower ranging from 0.08 per 
TB patient in Amajuba to 0.58 per TB patient in 
uMzinyathi. Excluding eThekwini and uMgungun-
dlovu the high burden of MDR TB in uMzinyathi 
and uMkhanyakude is not significantly correlated 
with the proportion of TB patients whose sputa 
were cultured (ρ = 0.451; p = 0.19). 
HIV prevalence 
In 2006 39.0% ± 1.2% of women attending 
antenatal clinics in KZN were HIV-positive and 
there was no significant variation among districts 
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apart from uMzinyathi where the prevalence, 
27.9% (23.0%−32.8%), was significantly below the 
provincial average. 
Treatment outcomes 
All TB cases 
In 2005 the treatment success rate for TB in the 
province was 63% among new and 50% among 
retreatment cases, well below the 80% target. The 
treatment success rate was highest in uMzinyathi at 
71% in new and 54% in retreatment cases. Default 
rates were high in eThekwini (23%) and uThukela 
(18%), death rates were high in Amajuba (15%), 
Zululand (14%), uMzinyathi (13%), and 
uMkhanyakude (10%), and the proportion ‘not 
evaluated’ was high in uMgungundlovu (34%), 
Ugu (28%) and uThungulu (21%). The reported 
treatment success rates at COSH were low, at only 
27%, but 68% of their patients were transferred out 
to primary health care facilities within the 
catchment area of the hospital and reported as such. 
Since the first-line treatment outcomes (71% 
treatment success) for the district (uMzinyathi) are 
among the best in the province, poor treatment 
outcomes are unlikely to explain the outbreak of 
XDR in the province.  
 
 
 
 
 
 
 
 
 
Figure 3. Treatment outcomes for 729 patients admitted 
to KGV with fully sensitive or mono-resistant TB, 2315 
with MDR TB and 54 with XDR TB. 
MDR and XDR treatment outcomes 
Figure 3 gives the treatment outcomes for 3098 TB 
patients admitted to KGV between 1994 and 2005. 
XDR patients were more likely than MDR patients 
to die (OR 1.45; 0.76−2.79, not significant) and less 
likely to be cured (OR 0.44; 95% CL 0.21−0.94). 
 However, the treatment success rate for MDR 
patients from uMzinyathi was 12.0% 
(5.5%−18.5%), considerably below the provincial 
average of 44%, while in uMkhanyakude it was 
38.4% (34.5−42.2%), only slightly below the 
provincial average. The low treatment success rates 
in uMzinyathi were associated with higher than 
average default rates, 28.0% (19.0%−37.0%), and 
death rates, 32.0% (22.7%−41.3%) but lower than 
average failure rates 12.0% (5.5%−18.5%). We 
therefore examined the treatment outcomes more 
carefully in the four hospitals in uMzinyathi. 
MDR and XDR in uMzinyathi  
The number of MDR TB cases as a proportion of 
the catchment population varies among the four 
hospitals in uMzinyathi District and, as shown in  
Figure 4, is significantly higher in COSH than in the 
other three: Charles Johnson Memorial (CJM), 
Dundee (DUN), or Greytown (GTN) Hospitals. 
However, in 2006, COSH took 1,300 cultures per 
catchment population, 26 times as many as in 
Dundee where they took 50 cultures per catchment 
population and this could explain the different rates 
within the district.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4. A: The number of MDR cases per 100k 
catchment population (left) and B: the proportion of 
MDR cases that were XDR (right) for patients tested at 
IALCH from 2005 to 2007. CJM: Charles Johnson 
Memorial; COSH: Church of Scotland; DUN: Dundee; 
GRTN: Greytown (GTN) Hospitals. 
 There was less variation in XDR as a proportion 
of MDR than in MDR as a proportion of all TB 
patients among the district hospitals as this depends 
less on the proportion of patients whose sputa are 
cultured. The proportion of MDR cases that were 
XDR in COSH is 2.4 times the average of the other 
three in 2005-2007. 
MDR TB treatment 
Between 1998 and 2007 the number of MDR-TB 
cases admitted to KGV increased by a factor of 
eight, from 147 to 1086, while the number of XDR 
TB cases increased from less than two cases per 
year up to 2004, to 31 in 2005 and 148 in 2007. 
Because the number of beds did not increase the 
average length of stay fell from six months in 1998 
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to two months in 2007, excluding those who died in 
the hospital. This led to an increase in the 
proportion of MDR TB patients with a positive 
smear or culture on discharge; between 2000 and 
2005, the proportion of patients who were smear 
positive on discharge fell from 15% to 5% but rose 
again to 17% in 2006 while the proportion who 
were culture positive on discharge rose from 25% 
in 2005 to 33% in 2006. 
 The prevalence of HIV among patients admitted 
to KGV was high in both MDR (72.4%; 
69.5%−75.4%) and XDR patients (76.2%; 
68.8%−83.6%) but a recent estimate suggests that 
73% of all TB cases in South Africa are HIV-
positive.1 These numbers do not suggest a strong 
association between HIV and MDR or XDR TB. 
MDR TB cases treated at KGV  
In 2006, only 30% of laboratory identified MDR 
cases in the province were admitted for MDR TB 
treatment and in order to cope with the increasing 
patient load, another 16% of all MDR cases were 
initiated on MDR TB treatment as outpatients with 
little or no support in their home areas which could 
be hundreds of kilometres away and with patients 
having to return monthly to KGV to collect 
medication. The remaining 54% (1505 MDR TB 
cases) had either died before receiving their 
diagnosis or remained untreated. In the same year 
the average time between sputum collection and 
admission to KGV was 16 weeks; on average it 
took three to six weeks to culture specimens and do 
DST, three weeks to return results to the referring 
health facility, three weeks to trace patients, and 
four to eight weeks to admit patients to KGV. 
 In 2005 the treatment success for all MDR 
patients at KGV was 40% but, given that over 70% 
of patients were infected with HIV, it is no worse 
than in other similar settings. However, uMzinyathi 
district had the highest default rates from MDR TB 
treatment in the province between 1996 and 2004.  
Potential for the spread of MDR TB from KGV 
hospital 
The highest MDR burdens as proportion of TB 
cases are in uMkhanyakude (4.8%) and uMzinyathi 
(4.1%) but the former has the lowest XDR rates in 
the province (1.0%) while the latter has the highest 
(46.8%). In the ten-year period from 1994 to 2004, 
prior to the outbreak of XDR TB in Tugela Ferry, 
167 patients from uMkhanyakude compared to 26 
patients from uMzinyathi were admitted to KGV 
for MDR treatment. The risk for developing, or 
contracting and spreading XDR was therefore 
higher in patients from uMkhanyakude than 
uMzinyathi. While it seems unlikely that poor 
treatment at KGV was the main reason for the 
outbreak seen in Tugela Ferry the rising demand for 
treatment at KGV without the necessary resources 
has increased the proportion of MDR TB patients 
being discharged while still infectious in 2006 
when 15% were smear positive and 46% were 
culture positive.  
Discussion  
Drug resistance burden 
The first two registered XDR TB patients in South 
Africa were admitted to KGV hospital for treatment 
in 2000 and both came from Durban (eThekwini). 
In 2007, in KZN 2.3% of all TB cases were MDR, 
close to the estimates from the 2002 National Drug 
Resistance Survey which gave 1.8% in new and 
5.5% in retreatment cases.10 While the drug 
sensitivity data from KZN after 2006 is fairly 
reliable, under-sampling may have led to under-
estimates of the true number of drug-resistant 
patients. There may also be less variation among 
districts than suggested by the available data 
because districts that reported a low MDR TB 
burden also took fewer samples for culture. Among 
the district hospitals within uMzinyathi, COSH had 
the highest MDR TB burden but also referred the 
greatest proportion of cases for culture. But, even 
accounting for differences in culture taking 
practices, MDR TB rates are particularly high in 
uMzinyathi, where XDR was first discovered in 
Tugela Ferry, and in uMkhanyakude, the coastal 
district that borders Mozambique.  
 XDR TB is present in all districts of the 
province but is more common in uMzinyathi than 
in the other districts in KZN. Within uMzinyathi, 
the extreme XDR burden is not unique to COSH 
and has probably spread to the other district 
hospitals, although COSH remains the worst 
affected. It seems that XDR TB has not spread 
much to other districts and in particular 
uMkhanyakude district has the lowest XDR TB 
burden (1.2% in 2007) in the province but the 
highest MDR TB burden (4.8% in 2007). 
 After 2004 XDR TB as proportion of MDR TB 
provides a robust indicator of trends in XDR TB for 
two reasons: 1) routine DST for first and second 
line TB drugs has been performed on the majority 
of samples since 2004, and 2) the XDR/MDR ratio 
is less dependant on the culture taking practice.  
Culture taking practice 
Using the expected number of cultures entails 
several assumptions regarding implementation of 
guidelines and estimates of cases requiring cultures. 
Using the population or reported TB burden as the 
denominator is also imprecise due to changes in 
case finding and reporting. However, the analysis 
presented here using any one of the three 
denominators gave similar results and gives some 
confidence in the results of the comparison. 
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 The strength of the analysis based on culture 
taking practice is that the data used in the 
numerator was cleaned and represents cases rather 
than samples. While the total number of samples 
cultured increased over the years, particularly after 
2005, it was not possible to determine the time 
trends per district for culture taking practice.  
Possible reasons for the emergence of drug 
resistance 
Suboptimal TB treatment  
By 1996, the South African National TB Control 
Programme (NTCP) was functional and based on 
the DOTS strategy. However, KZN did not adhere 
to the NTCP guidelines and used individualised 
treatment based on drug-sensitivity testing and 
DOTS was not promoted. In 2001, single drugs 
were replaced by fixed-dose combination drugs to 
ensure standardized treatment, and individualised 
treatment based on DST results was abandoned, 
which may have contributed to development of 
drug resistance in the province11 and treatment 
success rates in 2003 were low. 
 Particular circumstances may have allowed 
MDR development to reach high levels in 
uMkhanyakude and uMzinyathi. In several 
hospitals in uMkhanyakude, TB treatment was 
given two to three times per week with four drugs 
for six months without a separate intensive and 
continuation phase until 2001 when single drugs 
were replaced by fixed dose combination drugs. In 
uMzinyathi, because the geographical conditions 
made access to the hospital difficult, COSH 
regularly prescribed six-months TB treatment to 
spare patients from having to return monthly to 
collect further treatment although patients were 
followed up after two and six months. 
 The development of XDR TB implies 
suboptimal use of second line drugs. In uMzinyathi, 
a two-week course of ciprofloxacin was used only 
at COSH in the period 1998-2004 to treat HIV-
positive patients suffering from diarrhoea. In the 
rest of the province, ciprofloxacin was used in a 
one-day course of 500 mg for the syndromic 
management of gonorrhoea. Any other use of 
ciprofloxacin is restricted due to provincial 
regulations. Kanamycin and amikacin were rarely 
used in the province except for the treatment of TB. 
HIV prevalence and poor TB programme 
High HIV prevalence and poor TB programme 
performance could also have contributed to 
development of drug resistance in a particular area. 
However, HIV prevalence was no higher in 
uMzinyathi than in any other district; similarly, TB 
programme performance in uMzinyathi between 
2002 and 2005 was not worse than in other 
districts. Hence, neither HIV prevalence nor poor 
TB programme performance are likely to explain 
the exceptionally high rates of drug resistant TB in 
uMzinyathi although both may contribute to the 
overall problem of drug resistance in the province.  
MDR TB treatment 
The number of patients admitted to KGV has 
increased beyond the capacity of the hospital to 
treat them adequately resulting in long waiting 
times for treatment and a large proportion of MDR 
TB patients never receiving treatment. While this 
could have contributed to the transmission of drug-
resistant TB in the province it is unlikely to have 
caused the surge of XDR TB in uMzinyathi. On the 
other hand, the high rate of defaults and transfers-
out in uMzinyathi in the decade prior to the XDR 
outbreak may have contributed to the spread of 
second line drug resistance in that district. 
Lack of infection control in congregate settings 
Until very recently awareness of TB infection 
control has been low throughout the province. Prior 
to the start of the national rollout of ART in 2004 
COSH ran an effective and comprehensive HIV 
programme (Dr. T. Moll, pers. comm.) in which 
HIV patients were frequently hospitalised and 
treated for opportunistic infections, and where TB 
and HIV services were integrated at facility level. 
However, due to the lack of adequate facilities, TB 
and HIV patients were brought together in waiting 
rooms, at VCT sites, in TB and HIV clinics, in 
patient education classes, and in hospital wards, all 
of which were overcrowded and unventilated thus 
facilitating the transmission of TB, including MDR 
and XDR TB. In other sites at the time there was 
much less HIV testing and ART provision, and the 
TB and HIV programmes were not so integrated. 
Furthermore, a large proportion of XDR TB 
appears to have been acquired through primary 
infection, some of it due to a significant amount of 
nosocomial transmission at COSH.2 
Conclusion 
It has been suggested that multi drug-resistant 
(MDR) and extensively drug-resistant (XDR) 
tuberculosis (TB) epidemics are rapidly expanding 
in South Africa and the high death rates in those 
with XDR generated considerable alarm.12 
However, this study reveals that, within KZN 
province, high rates of XDR-TB were restricted to 
uMzinyathi district, and COSH in particular. It may 
never be possible to know precisely how XDR TB 
arose in COSH, but a number of factors are likely 
to have contributed to its emergence, including the 
integration of the TB and HIV programmes without 
sufficient infection control measures, and empirical 
use of fluoroquinolones for relatively long periods 
in patients with advanced HIV infection. Other 
factors that are present throughout the province and 
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which may have contributed to the emergence of 
XDR TB at COSH include high HIV prevalence 
and suboptimal TB management.  
 Outside uMzinyathi, the levels of MDR found 
in this study were sufficiently high to give rise to 
the concern that, together with suboptimal TB 
management, high levels of HIV in patients 
attending hospital, and insufficient infection control 
measures in place, XDR-TB could develop, and 
spread, in many other districts in the province.  
 A number of measures are vital to minimise the 
likelihood of this happening. First, surveillance to 
monitor MDR and XDR trends, is essential, and the 
policy of routine drug susceptibility testing for all 
culture positive isolates at IALCH is a step in the 
right direction, but needs to be backed up by 
clinicians requesting culture examination whenever 
clinically indicated. Second, case finding and case 
management of MDR needs considerable 
strengthening, both to ensure good support for 
ambulatory care of TB patients, especially for those 
who cannot be admitted to King George V, and also 
for those who are managed at KGV. Third, TB 
infection control must be strengthened in all health 
care facilities as a matter of urgency. If these 
improvements are made there is every reason to 
believe that drug-resistant TB can be managed 
effectively in the province. 
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